MME
Neprilysin
As of the edition of 20 October 2026, MME (neprilysin, UniProt P08473) has 7 drugs tested at it and 7 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08473
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 16
- Disease areas
- Heart and blood vessels; Urinary and reproductive; Cancer; Nutrition and metabolism; Pregnancy and women's health; Lungs and airways; Hormones; Infections
- Registered trials of its drugs
- 179
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sacubitril | Marketed | Phase 4 | Ends 2027 |
| Racecadotril | Marketed | Phase 3 | none listed |
| Ecadotril | Active | Phase 2 | none listed |
| LCZ 696 | Stopped | Phase 4 | none listed |
| Daglutril | Went quiet | Phase 2 | none listed |
| STR-324 | Active | Phase 2 | none listed |
| Ilepatril | Went quiet | Phase 3 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 4 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Sanofi | Route A |
| Solvay Pharmaceuticals | Route A |
The other 4 companies at MME
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at MME, ranked, with the facts behind eachRequest access. Nothing is shown until you do.